Targeting EPO/EPOR axis in cancer: advances and challenges in nano-enabled delivery
The immunosuppressive tumor microenvironment (TME) is a major obstacle to effective cancer immunotherapy by promoting immune evasion and disease progression. Recent studies suggest that erythropoietin (EPO), a glycoprotein hormone traditionally associated with erythropoiesis, also functions as an emerging regulator of tumor immune remodeling in a context-dependent manner. Tumor-derived EPO can influence tumor-associated macrophages and type 1 conventional dendritic cells by engaging with the erythropoietin receptor (EPOR) expressed on those immune cell surfaces, thereby reshaping the immunosuppressive TME and facilitating immune escape. Targeting the EPO/EPOR axis has therefore emerged as a promising strategy for cancer immunotherapy, with anti-EPOR neutralizing antibodies, siRNA silencing and antagonists yielding encouraging preclinical efficacy. Nevertheless, clinical translation remains challenging because of the essential physiological role of EPO/EPOR signaling in erythropoiesis, potential off-target toxicity, and the difficulty of selectively blocking pathological signaling while preserving normal hematopoietic function. Nano delivery systems provide new opportunities for precise modulation of the EPO/EPOR axis by improving targeting specificity and minimizing systemic toxicity. This review systematically examines the evolving understanding of the EPO/EPOR axis in tumor immunity, discusses the advances and limitations of current targeting strategies, and highlights the opportunities of nano delivery systems for precision targeting of the EPO/EPOR axis in cancer immunotherapy.
Authors
- Yan Hu (ORCID: https://orcid.org/0000-0003-2905-9295)
- Jiayi Sun
- Xuesha Xing
- Wei Jiang
- Qiang Liu
- Mingrui Dai
Institutions
- Dalian University of Technology (CN)
- Dalian Municipal Central Hospital (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1186/s12951-026-05235-y
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00